| scholarly article | Q13442814 |
| P2093 | author name string | Li R | |
| Shen Y | |||
| McGeer PL | |||
| McGeer EG | |||
| P2860 | cites work | Human complement component C3: cDNA coding sequence and derived primary structure | Q24568206 |
| Isolation of cDNA clones for human complement component C2 | Q24597623 | ||
| Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9 | Q24606396 | ||
| In situ hybridization of nucleus basalis neurons shows increased beta-amyloid mRNA in Alzheimer disease | Q33554297 | ||
| The structural basis of the multiple forms of human complement component C4. | Q34263330 | ||
| Molecular cloning and characterization of the complementary DNA and gene coding for the B-chain of subcomponent C1q of the human complement system | Q36424257 | ||
| Complement biosynthesis in the central nervous system | Q40406085 | ||
| Complement mRNA in the mammalian brain: responses to Alzheimer's disease and experimental brain lesioning | Q46128976 | ||
| Structural homology of human complement component C8 gamma and plasma protein HC: identity of the cysteine bond pattern | Q48333256 | ||
| Neurons express proteins of the classical complement pathway in Alzheimer disease. | Q48592170 | ||
| Complement-mediated neurotoxicity is regulated by homologous restriction. | Q49322431 | ||
| Diagnosis of Alzheimer's disease | Q69871134 | ||
| The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases | Q71674774 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 391-395 | |
| P577 | publication date | 1997-09-01 | |
| P1433 | published in | Brain Research | Q4955782 |
| P1476 | title | Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. | |
| P478 | volume | 769 |
| Q34809064 | A role for local inflammation in the formation of drusen in the aging eye. |
| Q44241464 | Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. |
| Q34425904 | Alzheimer's disease risk genes and mechanisms of disease pathogenesis |
| Q36456719 | Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease. |
| Q35114490 | Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease |
| Q36346078 | C1q ablation exacerbates amyloid deposition: A study in a transgenic mouse model of ATTRV30M amyloid neuropathy. |
| Q43187968 | C1q, the recognition subcomponent of the classical pathway of complement, drives microglial activation. |
| Q41688205 | C1qB and clusterin mRNA increase in association with neurodegeneration in sporadic amyotrophic lateral sclerosis |
| Q92022259 | CD4+ T cell expression of the IL-10 receptor is necessary for facial motoneuron survival after axotomy |
| Q40306336 | Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain |
| Q40842986 | Characterization of the murine homolog of C1qR(P): identical cellular expression pattern, chromosomal location and functional activity of the human and murine C1qR(P). |
| Q92450988 | Classical complement cascade initiating C1q protein within neurons in the aged rhesus macaque dorsolateral prefrontal cortex |
| Q43249892 | Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease |
| Q42001466 | Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice |
| Q77659337 | Complement activation and CD59 expression in the motor facial nucleus following intracranial transection of the facial nerve in the adult rat |
| Q33974402 | Complement components of the innate immune system in health and disease in the CNS. |
| Q37872442 | Complement in the brain. |
| Q37031176 | Complement is activated in progressive multiple sclerosis cortical grey matter lesions |
| Q48182145 | Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease |
| Q43906657 | Constitutive expression of proinflammatory complement components by subsets of neurons in the central nervous system |
| Q34550347 | Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease |
| Q41942305 | De-regulation of gene expression and alternative splicing affects distinct cellular pathways in the aging hippocampus. |
| Q73066482 | Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease |
| Q73816088 | Degeneration process of Lewy bodies in the brains of patients with dementia with Lewy bodies using alpha-synuclein-immunohistochemistry |
| Q53237812 | Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. |
| Q24791689 | Differential regulation of Abeta42-induced neuronal C1q synthesis and microglial activation |
| Q39217121 | Dynamics of the Complement, Cytokine, and Chemokine Systems in the Regulation of Synaptic Function and Dysfunction Relevant to Alzheimer's Disease |
| Q33589732 | ER stress in Alzheimer's disease: a novel neuronal trigger for inflammation and Alzheimer's pathology |
| Q74419354 | Effects of C-reactive protein and pentosan polysulphate on human complement activation |
| Q93186105 | Emerging Roles of Complement in Psychiatric Disorders |
| Q90107218 | Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease |
| Q48364009 | Expression of complement C4 and C9 genes by human astrocytes |
| Q48317953 | Expression of complement messenger RNAs and proteins by human oligodendroglial cells |
| Q40869692 | Expression of complement messenger RNAs by human endothelial cells |
| Q37443394 | Expression of complement system components during aging and amyloid deposition in APP transgenic mice |
| Q36926809 | Gene expression changes in the course of normal brain aging are sexually dimorphic |
| Q48964629 | Glial involvement in the degeneration process of Lewy body-bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies. |
| Q49124233 | Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. |
| Q24791117 | Human oligodendroglial cells express low levels of C1 inhibitor and membrane cofactor protein mRNAs |
| Q42044152 | Human postmortem brain-derived cerebrovascular smooth muscle cells express all genes of the classical complement pathway: a potential mechanism for vascular damage in cerebral amyloid angiopathy and Alzheimer's disease |
| Q38675216 | Immunotherapies in Alzheimer's disease: Too much, too little, too late or off-target? |
| Q47744250 | Induced expression of neuronal membrane attack complex and cell death by Alzheimer's beta-amyloid peptide |
| Q43638529 | Induction of complement C9 messenger RNAs in human neuronal cells by inflammatory stimuli: relevance to neurodegenerative disorders |
| Q36177112 | Induction of complement proteins in a mouse model for cerebral microvascular A beta deposition |
| Q28138617 | Inflammation and Alzheimer's disease |
| Q33678241 | Inflammatory pathogenesis in Alzheimer's disease: biological mechanisms and cognitive sequeli |
| Q48830389 | Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. |
| Q37574396 | Innate immunity in the nervous system |
| Q33474266 | Inosine alters gene expression and axonal projections in neurons contralateral to a cortical infarct and improves skilled use of the impaired limb |
| Q33733863 | Late onset Alzheimer's disease genetics implicates microglial pathways in disease risk |
| Q42091159 | Microarray analysis identifies changes in inflammatory gene expression in response to amyloid-beta stimulation of cultured human retinal pigment epithelial cells |
| Q28565397 | Microarray reveals complement components are regulated in the serum-deprived rat retinal ganglion cell line |
| Q34963822 | Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide |
| Q33940339 | Microglia and neurodegeneration |
| Q42322507 | Microglia, Alzheimer's disease, and complement |
| Q36902290 | Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? |
| Q34963776 | Neuroinflammation in Alzheimer's disease and prion disease. |
| Q48592170 | Neurons express proteins of the classical complement pathway in Alzheimer disease. |
| Q47900581 | Preconditioning reduces tissue complement gene expression in the rabbit isolated heart |
| Q36124489 | Role of formyl peptide receptor-like 1 (FPRL1/FPR2) in mononuclear phagocyte responses in Alzheimer disease |
| Q34560179 | Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities. |
| Q36483870 | Signaling pathways regulating neuron-glia interaction and their implications in Alzheimer's disease |
| Q39307376 | State of Play in Alzheimer's Disease Genetics |
| Q40853980 | The C5a complement activation peptide increases IL-1beta and IL-6 release from amyloid-beta primed human monocytes: implications for Alzheimer's disease |
| Q90813046 | The complement cascade in Alzheimer's disease: a systematic review and meta-analysis |
| Q34325902 | The complement system in central nervous system diseases |
| Q40856171 | The future use of complement inhibitors for the treatment of neurological diseases |
| Q43907611 | The human complement C9 gene: structural analysis of the 5' gene region and genetic polymorphism studies |
| Q48380991 | The importance of inflammatory mechanisms in Alzheimer disease |
| Q33971345 | The role of complement in Alzheimer's disease pathology |
| Q77208461 | The role of the complement system in traumatic brain injury |
| Q33282966 | Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons |
| Q90521855 | Transneuronal Downregulation of the Premotor Cholinergic System After Corticospinal Tract Loss |
| Q47751388 | Understanding AMD by analogy: systematic review of lipid-related common pathogenic mechanisms in AMD, AD, AS and GN. |
| Q35786312 | Up-regulated production and activation of the complement system in Alzheimer's disease brain |
| Q35191570 | Upregulation of glycolytic enzymes, mitochondrial dysfunction and increased cytotoxicity in glial cells treated with Alzheimer's disease plasma |
| Q24796236 | Using animal models to determine the significance of complement activation in Alzheimer's disease |
| Q37368120 | What does complement do in Alzheimer's disease? Old molecules with new insights |
| Q35563953 | Yin and Yang: complement activation and regulation in Alzheimer’s disease |
Search more.